TY - JOUR
T1 - Quality Indicators for the Management of Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma
T2 - International Consensus Recommendations from the American Gastroenterological Association Symposium
AU - Sharma, Prateek
AU - Katzka, David A.
AU - Gupta, Neil
AU - Ajani, Jaffer
AU - Buttar, Navtej
AU - Chak, Amitabh
AU - Corley, Douglas
AU - El-Serag, Hashem
AU - Falk, Gary W.
AU - Fitzgerald, Rebecca
AU - Goldblum, John
AU - Gress, Frank
AU - Ilson, David H.
AU - Inadomi, John M.
AU - Kuipers, Ernest J.
AU - Lynch, John P.
AU - McKeon, Frank
AU - Metz, David
AU - Pasricha, Pankaj J.
AU - Pech, Oliver
AU - Peek, Richard
AU - Peters, Jeffrey H.
AU - Repici, Alessandro
AU - Seewald, Stefan
AU - Shaheen, Nicholas J.
AU - Souza, Rhonda F.
AU - Spechler, Stuart J.
AU - Vennalaganti, Prashanth
AU - Wang, Kenneth
N1 - Publisher Copyright:
© 2015 AGA Institute.
PY - 2015/11
Y1 - 2015/11
N2 - The development of and adherence to quality indicators in gastroenterology, as in all of medicine, is increasing in importance to ensure that patients receive consistent high-quality care. In addition, government-based and private insurers will be expecting documentation of the parameters by which we measure quality, which will likely affect reimbursements. Barrett's esophagus remains a particularly important disease entity for which we should maintain up-to-date guidelines, given its commonality, potentially lethal outcomes, and controversies regarding screening and surveillance. To achieve this goal, a relatively large group of international experts was assembled and, using the modified Delphi method, evaluated the validity of multiple candidate quality indicators for the diagnosis and management of Barrett's esophagus. Several candidate quality indicators achieved >80% agreement. These statements are intended to serve as a consensus on candidate quality indicators for those who treat patients with Barrett's esophagus.
AB - The development of and adherence to quality indicators in gastroenterology, as in all of medicine, is increasing in importance to ensure that patients receive consistent high-quality care. In addition, government-based and private insurers will be expecting documentation of the parameters by which we measure quality, which will likely affect reimbursements. Barrett's esophagus remains a particularly important disease entity for which we should maintain up-to-date guidelines, given its commonality, potentially lethal outcomes, and controversies regarding screening and surveillance. To achieve this goal, a relatively large group of international experts was assembled and, using the modified Delphi method, evaluated the validity of multiple candidate quality indicators for the diagnosis and management of Barrett's esophagus. Several candidate quality indicators achieved >80% agreement. These statements are intended to serve as a consensus on candidate quality indicators for those who treat patients with Barrett's esophagus.
KW - Barrett's Esophagus
KW - Barrett's Surveillance
KW - Consensus Statements
KW - Endoscopic Mucosal Resection
KW - Esophageal Adenocarcinoma
KW - Gastroesophageal Reflux Disease
KW - High-Grade Dysplasia
KW - Low-Grade Dysplasia
KW - Metastatic Esophageal Adenocarcinoma
KW - Prague Criteria
KW - Proton Pump Inhibitors
KW - Quality Indicators
KW - Radiofrequency Ablation
UR - http://www.scopus.com/inward/record.url?scp=84945581995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945581995&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2015.08.007
DO - 10.1053/j.gastro.2015.08.007
M3 - Article
C2 - 26296479
AN - SCOPUS:84945581995
SN - 0016-5085
VL - 149
SP - 1599
EP - 1606
JO - Gastroenterology
JF - Gastroenterology
IS - 6
ER -